Insider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Acquires 46,620 Shares of Stock

Key Points

• Director Ramiro Guerrero purchased 46,620 MAIA shares at an average price of $1.35, investing $62,937 and increasing his ownership by 6.77% to 735,701 shares. He also made four other purchases between August 20 and 27.
• MAIA shares fell 0.8% to $1.30, below their 50-day and 200-day moving averages of $1.37 and $1.44, respectively; the stock has traded between $0.87 and $3.19 over the past year.
• The clinical-stage biopharmaceutical company reported a quarterly loss of $0.13 per share, missing estimates by $0.02, while institutional investors own 5.65% of its stock.

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Ramiro Guerrero bought 46,620 shares of the company's stock in a transaction dated Friday, August 28th. The stock was bought at an average price of $1.35 per share, for a total transaction of $62,937.00. Following the transaction, the director owned 735,701 shares of the company's stock, valued at approximately $993,196.35. This trade represents a 6.77% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Ramiro Guerrero also recently made the following trade(s):

• On Thursday, August 27th, Ramiro Guerrero purchased 78,239 shares of MAIA Biotechnology stock. The shares were bought at an average price of $1.39 per share, with a total value of $108,752.21.
• On Wednesday, August 26th, Ramiro Guerrero purchased 8,931 shares of MAIA Biotechnology stock. The stock was bought at an average cost of $1.39 per share, for a total transaction of $12,414.09.
• On Monday, August 24th, Ramiro Guerrero acquired 1,794 shares of MAIA Biotechnology stock. The stock was purchased at an average price of $1.33 per share, for a total transaction of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero acquired 11,899 shares of MAIA Biotechnology stock. The shares were purchased at an average price of $1.37 per share, with a total value of $16,301.63.

MAIA Biotechnology Trading Down 0.8%

NYSEAMERICAN:MAIA traded down $0.01 during trading hours on Tuesday, hitting $1.30. 304,095 shares of the stock were exchanged, compared to its average volume of 791,682. The firm's fifty day moving average price is $1.37 and its 200 day moving average price is $1.44. MAIA Biotechnology, Inc. has a 52-week low of $0.87 and a 52-week high of $3.19. The company has a market cap of $79.08 million, a P/E ratio of -2.10 and a beta of 0.24.

MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities analysts expect that MAIA Biotechnology, Inc. will post -0.54 EPS for the current fiscal year.

Institutional Investors Weigh In On MAIA Biotechnology

A number of large investors have recently modified their holdings of MAIA. Marshall Wace LLP acquired a new stake in shares of MAIA Biotechnology in the second quarter valued at about $29,000. PVG Asset Management Corp purchased a new position in shares of MAIA Biotechnology in the first quarter worth about $46,000. Susquehanna International Group LLP acquired a new position in MAIA Biotechnology during the second quarter worth about $51,000. Jane Street Group LLC acquired a new position in MAIA Biotechnology during the second quarter worth about $52,000. Finally, Corsair Capital Management L.P. purchased a new stake in MAIA Biotechnology during the 1st quarter valued at about $140,000. Hedge funds and other institutional investors own 5.65% of the company's stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source